Anti-VEGF and Anti-EGFR Antibody Therapy on T-Cell Infiltration and TCR Variation in Metastatic Colorectal Cancer
M Xu, R Tsunedomi, K Kiyotani, S Tomochika… - Anticancer …, 2023 - ar.iiarjournals.org
Background/Aim: Chemotherapy combined with anti-EGFR or anti-VEGF monoclonal
antibodies (mAb) is widely used to treat patients with metastatic colorectal cancer (mCRC) …
antibodies (mAb) is widely used to treat patients with metastatic colorectal cancer (mCRC) …
[HTML][HTML] Immune cell infiltration of the primary tumor microenvironment predicted the treatment outcome of chemotherapy with or without bevacizumab in metastatic …
Y Wang, J Dong, Q Quan, S Liu, X Chen, X Cai… - Frontiers in …, 2021 - frontiersin.org
Background With the interest in cancer immunotherapy, it may be possible to combine
immunotherapy with bevacizumab and chemotherapy. We evaluated whether tumor …
immunotherapy with bevacizumab and chemotherapy. We evaluated whether tumor …
The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy
M Roselli, V Formica, V Cereda, C Jochems… - …, 2016 - Taylor & Francis
The first-line standard of care for patients with metastatic colorectal cancer (mCRC) is
FOLFIRI (irinotecan, levo-leucovorin, 5-fluorouracil (5-FU)) plus bevacizumab. With the …
FOLFIRI (irinotecan, levo-leucovorin, 5-fluorouracil (5-FU)) plus bevacizumab. With the …
Combining anti-epidermal growth factor receptor (EGFR) therapy with immunotherapy in metastatic colorectal cancer (mCRC)
F Xiong, YW Zhou, YT Hao, GX Wei… - Expert Review of …, 2024 - Taylor & Francis
Introduction Monoclonal antibodies binding the EGFR, such as cetuximab and
panitumumab, have been extensively used as targeted therapy for the treatment of mCRC …
panitumumab, have been extensively used as targeted therapy for the treatment of mCRC …
[HTML][HTML] Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective …
B Bencsikova, E Budinska, I Selingerova, K Pilatova… - BMC cancer, 2019 - Springer
Background In a prospective study with long-term follow-up, we analyzed circulating T cell
subsets in patients with metastatic colorectal cancer (mCRC) in the context of primary tumor …
subsets in patients with metastatic colorectal cancer (mCRC) in the context of primary tumor …
[HTML][HTML] Changes of TCR repertoire diversity in colorectal cancer after Erbitux (cetuximab) in combination with chemotherapy
W Luo, WT He, Q Wen, S Chen, J Wu… - American Journal of …, 2014 - ncbi.nlm.nih.gov
We have previous found a positive correlation between post-therapy TCR repertoire
normalization and remission of colorectal cancer (CRC) patients following fluorouracil …
normalization and remission of colorectal cancer (CRC) patients following fluorouracil …
Chemotherapy±cetuximab modulates peripheral immune responses in metastatic colorectal cancer
ID Xynos, ML Karadima, IF Voutsas, S Amptoulach… - Oncology, 2013 - karger.com
Objective: To identify changes in peripheral immune responses in patients with metastatic
colorectal cancer (mCRC) treated with irinotecan/5-fluorouracil/leucovorin (IFL) alone or in …
colorectal cancer (mCRC) treated with irinotecan/5-fluorouracil/leucovorin (IFL) alone or in …
Anti-VEGF and anti-EGFR monoclonal antibodies (Mabs) in the first-line therapy for metastatic colorectal cancer: A meta-analysis
Z Zhou, WV Walsh, VG Bathini… - Journal of Clinical …, 2009 - ascopubs.org
e15012 Background: Anti-VEGF (VEGFi) and anti-EGFR (EGFRi) Mabs have increased
options for patients with metastatic colorectal cancers (mCRC). The optimal class of antibody …
options for patients with metastatic colorectal cancers (mCRC). The optimal class of antibody …
[HTML][HTML] Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: a pooled analysis of five prospective …
R Moretto, S Corallo, A Belfiore, D Rossini… - European Journal of …, 2020 - Elsevier
Background Immune-contexture of tumour microenvironment (TME) influences prognosis of
colorectal cancer (CRC) patients and can be altered by cytotoxic and targeted agents …
colorectal cancer (CRC) patients and can be altered by cytotoxic and targeted agents …
Combined treatment with bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patients
N Tsavaris, IF Voutsas, C Kosmas, AD Gritzapis… - Investigational new …, 2012 - Springer
Background Bevacizumab, a monoclonal antibody (mAb) targeting vascular endothelial
growth factor (VEGF), has produced promising results when combined with chemotherapy in …
growth factor (VEGF), has produced promising results when combined with chemotherapy in …